Introduction
Intrathyroid thymic carcinoma (ITTC)/carcinoma showing thymus-like
differentiation (CASTLE) is a rare cancer with slow growth which bears
histological similarity with thymic carcinomas and clinically shows
positive treatment responses 1. Occasionally, ITTC
metastasizes into lymph nodes and/or to distant organs, resulting in a
poor prognosis 2,3. However, no effective drugs have
been developed for controlling metastatic ITTC. Herein, to explore new
therapeutic strategies for a metastatic ITTC, we uncovered specific
genetic mutation and immune microenvironment profiles in metastatic ITTC
by next-generation sequencing (NGS), multiplex immunohistochemistry and
imaging cytometry.